 |
Photo = Celtrion |
[Alpha Biz= Paul Lee] SEOUL, South Korea – June 12, 2025 — Once ranked as high as third in market capitalization on the KOSPI, Celltrion (KRX: 068270) has now dropped to 11th place, as investor sentiment weakens due to disappointing earnings performance and dim short-term profit outlook.
As of June 12, Celltrion shares closed at ₩163,900, down 5.59% year-to-date, significantly underperforming the KOSPI index, which has risen 21.5% over the same period. The KRX Healthcare Index has also gained 8.27% this year, further highlighting Celltrion’s relative underperformance in its sector.
Celltrion’s current market capitalization stands at approximately ₩36.46 trillion, trailing behind Kia Corp. (₩39.13 trillion) and HD Hyundai Heavy Industries (₩37.24 trillion). Doosan Enerbility, a recent market gainer, is rapidly narrowing the gap with a market cap of ₩34.97 trillion.
Back in 2018, Celltrion reached its all-time high in earnings and enjoyed a rally fueled by its inclusion in the KOSPI 200 index, briefly pushing its market cap above ₩35 trillion, ahead of Hyundai Motor. However, its market value has seen little progress over the past seven years.
In Q1 2025, Celltrion reported an operating profit of ₩149 billion, nearly 30% below consensus estimates, primarily due to weak sales of Zymfentra and increased startup costs at its new manufacturing facilities. This figure also pales in comparison to its Q1 2018 profit of ₩350 billion.
Nevertheless, analysts expect a recovery in the second half of 2025, with rising sales of Remsima SC anticipated to lift overall earnings — raising hopes that Celltrion’s stock may have found a bottom.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
